Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Diabetologia. 2020 Oct 1;64(1):159–167. doi: 10.1007/s00125-020-05281-7

Fig. 1.

Fig. 1

The change in the fraction of new adipocytes was significant in the scFEM, but not the scABD depot in the pioglitazone group compared with the placebo group. The least square means comparing the change (post-intervention – baseline) in the fraction of new adipocytes in the pioglitazone vs the placebo group were derived from the linear mixed-effects model (n=41). The change in the fraction of new adipocytes between the pioglitazone and placebo groups in the scFEM depot is 3.3±1.6% (p=0.04), while the change in the fraction of new adipocytes between the treatment groups in the scABD depot is 2.0±2.1% (p=0.32). Values presented as means ± SEM. Dark grey bars, placebo; light grey bars, pioglitazone